Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 15/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12065135 | 0.92 | MEN1 (0.70) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL14035317 | 0.83 | CHRM2 (0.49) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL8458368 | 0.83 | CHRM2 (0.49) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL14035488 | 0.83 | CHRM2 (0.49) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL336219 | 0.79 | CYP2D6 (0.67) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL30331028 | 0.79 | SLC6A4 (0.42) | CYP2D6CYP19A1 | |
| SCHEMBL12065134 | 0.77 | MEN1 (0.62) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL12656443 | 0.77 | OGA (0.40) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL16226307 | 0.76 | OPRD1 (0.63) | CYP2D6CYP19A1MEN1KMT2AOPRD1 | |
| SCHEMBL30330150 | 0.76 | TACR1 (0.46) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546103-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1546103-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMA (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20040180880-A1 | Piperazine and piperidine derivatives | LAUFFER DAVID J (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2004031148-A1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180880-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | CYP2D6 4847/4885CYP19A1 3756/4885MEN1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.